Open Data for Predictive Biology
Biohub, DOE, NIH and funding partners, announced 7 October 2026. Amounts are as stated in the release.
Virtual Biology Initiative expansion
$1.8 billion in funding, data, compute and tech
U.S. Department of Energy
More than $500 million over 5 years
Measure, model and compute
National Institutes of Health
Datasets from more than $500 million
Prior federal investment
Three AI companies
$300 million collectively
DeepMind, Isomorphic and Meta
Biohub
$500 million founding commitment
$400 million tech, $100 million external
What the release does not name
No therapeutic modality, disease area or clinical program
No model results, and no availability date for the open resource
Biohub press release, 7 October 2026. The release gives $1.8 billion as the combined figure.
Who is putting what into the open data effort, and what the announcement leaves unsaid
Biohub, DOE and NIH describe $1.8 billion in funding, data and compute for open, AI-ready biological data.
Here is where it could still reach a CGT budget, and where it does not.
On October 7, Biohub, the U.S. Department of Energy, the NIH and new funding partners announced an expansion of the Virtual Biology Initiative. GTC's read: upside to track, not a dependency, until the covered cell types and an availability date are published.
What was announced
Biohub, the U.S. Department of Energy, the NIH and new funding partners announced an expansion of an international effort on October 7. The effort aims to generate and make accessible the data enabling predictive AI models of biology.
They put the combined commitment at $1.8 billion in funding, data, computation and new measurement technology. The release calls it the largest coordinated commitment to generating AI-ready biological data to date.
The stated output is an open resource for the research community, described as the foundation for greater understanding and ultimately treatment of human diseases. The release body gives $1.8 billion; its headline rounds this to nearly $2 billion.
GTC's reading of the release's own figures: not all of the $1.8 billion is new money. NIH's share is datasets already built with more than $500 million in prior federal investment. Biohub's $500 million is its founding commitment to the initiative launched on April 29, 2026. DOE's more than $500 million and the companies' $300 million are both announced in this release.
By GTC's reading, more than half of the $1.8 billion is not new in the October 7 release: NIH's share is existing data, and Biohub's is its April commitment.
The announcement, in short
- Energy: DOE will invest more than $500 million over five years in lab measurement, modeling and computation, through the Genesis Mission.
- NIH: coordinating datasets, repositories and knowledge bases developed through more than $500 million in prior federal investment. Biohub will help standardize them for AI model training.
- Companies: Google DeepMind, Isomorphic Labs and Meta are collectively investing $300 million in the Virtual Biology Initiative.
- Biohub: a founding $500 million commitment, of which $400 million supports new measurement technologies and $100 million funds research outside Biohub.
- Named partners: the Allen Institute, Broad Institute, Gladstone Institutes, Human Cell Atlas, Human Protein Atlas and Wellcome Sanger Institute, with NVIDIA supporting computing and Renaissance Philanthropy helping expand funding.
What the data is meant to do
The release says the datasets will let researchers ask, predict and answer biological questions digitally. It says the initiative will expand cell response data to interventions across far more cell types and conditions than have yet been studied. It will also build and validate technologies for studying cells at greater scale, speed and accuracy.
Biohub says it is building the layer that lets partner datasets work in a unified fashion: shared standards, common identifiers and a single point of access. GTC's read: the first to benefit would be programs that already generate cell-response data for their own cell types. They could map it to a shared standard instead of a vendor's format.
Nicole Kleinstreuer, NIH Deputy Director for Program Coordination, Planning and Strategic Initiatives, says the aim is universal cell models able to predict how any cell responds to an intervention. She says the return could be substantially faster timelines for medical breakthroughs than laboratory experiments alone.
What the announcement does not say
The release does not name a therapeutic modality, a disease area or a clinical program. It does not mention gene therapy or cell therapy. Its treatment language stays general: understanding and ultimately treatment of human diseases.
It reports no model results and gives no date for the open resource. The only forward time span stated is DOE's five-year contribution.
What this means for a CGT program
GTC analysis: the four points below are our reading of the announcement, not statements in it.
The first budget line this could touch is reference data: a program whose cell types are covered could generate or buy less of it. Neither Biohub release lists the cell types covered. The release names earlier Biohub work the initiative builds on, including CELLxGENE and Tabula Sapiens, a rough guide a team can check its cell types against now.
Because no availability date is given, a program with an IND-enabling plan should keep the resource off the critical path and check back when the cell-type list appears.
On regulatory planning, nothing in the announcement changes what an IND has to contain. Model predictions can inform target and cell-type choices; they are not data a filing rests on.
For vendors, shared standards and common identifiers could make data-generation services easier to compare. A program commissioning a perturbation or single-cell study this year can add one line to the scope: outputs to be mapped to the initiative's standards once those are published.
If you have built or bought cell-response or perturbation datasets for a cell or gene therapy program, join GTC's Expert Network. It matches AI and data experts like you to paid consulting work: join free.
Frequently asked questions
What did Biohub, DOE and NIH announce on October 7, 2026?
Biohub, DOE, the NIH and new funding partners announced an expansion of an effort to generate the data that predictive AI models of biology need. They put the combined commitment at $1.8 billion in funding, data, computation and new measurement technology. The stated output is an open resource for the research community.
Who is contributing what?
DOE will invest more than $500 million over five years in lab measurement, modeling and computation. NIH will coordinate datasets, repositories and knowledge bases developed through more than $500 million in prior federal investment. Google DeepMind, Isomorphic Labs and Meta are collectively investing $300 million in the Virtual Biology Initiative, which Biohub anchors with a founding $500 million commitment.
Does the announcement mention gene therapy or cell therapy?
No. The release does not name a therapeutic modality, a disease area or a clinical program. It describes the goal as greater understanding and ultimately treatment of human diseases.
What is the Virtual Biology Initiative?
The Virtual Biology Initiative was announced in April 2026. The release says it will coordinate data generation across institutions to build AI-ready open datasets for predictive models of life. Biohub's founding $500 million commitment includes $400 million for new measurement technologies and $100 million for research outside Biohub.
Could this matter to a cell or gene therapy developer?
Not yet as a planning input. If the data cover a program's cell types and conditions, the team could generate less reference data itself, but the release gives no cell-type list and no availability date.
Sources
- International, cross-sector collaboration commits nearly $2 billion to build foundational data for AI models to predict and treat disease - Biohub, press release, October 7, 2026.
- Biohub Launches the Virtual Biology Initiative to Galvanize a Global Effort to Create the Open Data Foundation for AI-Accelerated Biology - Biohub, press release, April 29, 2026. Source for the April launch date and the original $500 million commitment.
Join the GTC Expert Network
Independent Experts
Independent experts in cell & gene therapy: share knowledge, help build a report, or contribute quietly. Build authority and get called for paid consulting work. Join free.
Early R&D Experts
Early R&D ExpertsContribute target validation, vector engineering, or transgene design expertise. Get matched to paid consulting work through content you help create.
Join FreeCMC Experts
CMC ExpertsContribute scale-up, tech transfer, or GMP manufacturing expertise. Get matched to paid consulting work through content you help create.
Join FreeRegulatory Affairs Experts
Regulatory Affairs ExpertsContribute IND/BLA strategy or regulatory liaison expertise. Get matched to paid consulting work through content you help create.
Join FreeCommercial & Strategy Experts
Commercial & Strategy ExpertsContribute due diligence, licensing, or market access expertise. Get matched to paid consulting work through content you help create.
Join FreeEnabling Technology Experts
Enabling Technology ExpertsContribute bioprocessing hardware, analytical tooling, or supply-chain expertise. Get matched to paid consulting work through content you help create.
Join FreeAI Transformation Experts
AI Transformation ExpertsContribute agentic workflow, LLM, or AI-driven vector design expertise. Get matched to paid consulting work through content you help create.
Join FreeIndustry Representatives
Industry professionals in cell & gene therapy: de-risk your pipeline with expert input on demand, exactly when your program needs it. Join free.
Drug Developers
Drug DevelopersFounders, CSOs, VPs of R&D
Practical guides spanning vector design through commercialization, plus direct access to the expert network that wrote them.
Join FreeInvestors / VCs
Investors / VCsVC Fund Managers, Family Offices, Angels
Due diligence frameworks and strategic intelligence for evaluating CGT assets, from experts who do this diligence for a living.
Join FreeTechnology Developers
Technology DevelopersFounders, Licensing & Commercial Leads
IP protection and platform strategy guides for enabling technologies, plus the network that built them.
Join FreeCDMOs / CROs
CDMOs / CROsBD, Operations & Technical Leads
Partner selection, vendor evaluation, and operational excellence guides, sourced from the CGT organisations that use them.
Join FreeVendors / Suppliers
Vendors / SuppliersCommercial & Technical Leads
Market intelligence and partnership strategies for supply chain companies serving cell and gene therapy.
Join FreeStrategy Consultants
Strategy ConsultantsConsultants, Market Access Advisors
Spot the problems before they cost your clients - join the network that shapes what GTC covers next.
Join FreeAI Transformation Partners
AI Transformation PartnersAI/ML Consultancies, Digital Transformation Firms
AI education, implementation, and consulting for operational excellence in cell and gene therapy - for companies building or buying AI capability.
Join FreeWhere the analysis comes from. Industry teams get expert input on demand; independent experts build authority and get called for paid consulting work.
See more of our work in Google Search
Google lets you pick the sites you want to see more often in Top Stories. Add Gene Therapy Consultancy to your list, and our daily gene therapy news will show up higher for you.